Finland· FI-REL-REL61972
Emblaveo
A aztreonam und beta-lactamase-inhibitor product containing aztreonam + avibactam sodium, registered in Finland by Pfizer Europe MA EEIG. The same ATC class is registered in 7 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Aztreonam und beta-lactamase-inhibitor is registered in 7 of 19 countries.
Countries holding a registration under ATC J01DF51 (aztreonam und beta-lactamase-inhibitor), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 4 of them publish a price we can compare per daily dose
Aztreonam und beta-lactamase-inhibitor · ATC J01DF51
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
The record
At a glance
Fimea (Finland)- Active substance
- Aztreonam + Avibactam sodium
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Finland (FI)
- ATC code
- J01DF51
- ATC class
- Aztreonam und Beta-Lactamase-Inhibitor
- Defined daily dose
- 6 g, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aztreonam und beta-lactamase-inhibitor in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesEMBLAVEOAbbVie Inc.
- SpainEMBLAVEO 1,5 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONPfizer Europe Ma Eeig
- FranceEMBLAVEO 1,5 g/0,5 g, poudre pour solution à diluer pour perfusionPFIZER EUROPE MA EEIG (BELGIQUE)
- United KingdomEmblaveo 1.5g/0.5g powder for concentrate for solution for infusion vialsPfizer Ltd
- IrelandEmblaveo 1.5 g/0.5 g powder for concentrate for solution for infusionPfizer Europe MA EEIG
- CzechiaEMBLAVEOPfizer Europe MA EEIG, Bruxelles
- NorwayEmblaveoPfizer Europe MA EEIG
- PolandEmblaveoPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Emblaveo
- Liechtenstein · Emblaveo
- Norway · Emblaveo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/99c3d34b-9514-4126-a0af-8eb1beb0e5eb GET /v1/drugs/99c3d34b-9514-4126-a0af-8eb1beb0e5eb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "6",
"form": "kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos",
"route": "Laskimoon",
"ddd_unit": "g",
"strength": "1.5 g / 0.5 g",
"atc_label": "atstreonaami ja beetalaktamaasin estäjä",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/24/1808/001",
"fimea_rel_id": "REL61972",
"authorised_at": "2024-04-22"
}See everything about aztreonam und beta-lactamase-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.